New Cancer-Focused Biotech Forty Seven Inc. Selects Medidata to Accelerate Novel Immuno-Oncology R&
Stanford University Startup Leverages Medidata’s Cloud Technology to Tackle Cancers with Limited Treatment Options
NEW YORK, N.Y.–– Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that Forty Seven Inc., a new biotechnology company specializing in cancer immunotherapy, is powering two upcoming anti-cancer studies with the Medidata Clinical Cloud®.
Formed by Stanford University researchers in 2015 and backed by Sutter Hill, Lightspeed, Clarus Ventures and Google’s GV, the venture capital arm of Alphabet, Inc., the Palo Alto, California-based biotech will leverage Medidata’s industry-leading electronic data capture, management and reporting system (Medidata Rave®) to advance therapies for cancers with highly unmet medical needs.
“The idea to form Forty Seven Inc. stemmed from a growing passion for science and pioneering breakthrough cancer solutions for patients. That’s why we feel strongly about partner

